Lumiracoxib
Lumiracoxib
Lumiracoxib (pronounced loo-mi-ra-cox-ib) is a nonsteroidal anti-inflammatory drug (NSAID) that was previously marketed by Novartis. It belongs to the class of COX-2 inhibitors, a subclass of NSAIDs. Lumiracoxib was used for the treatment of osteoarthritis in adults and acute pain in adults, but it was withdrawn from the market due to concerns about its side effects.
Etymology
The name "Lumiracoxib" is derived from the drug's mechanism of action. "Lumi" is derived from the Latin word for light, referring to the drug's ability to "light up" and inhibit the COX-2 enzyme. "Racoxib" is a common suffix for COX-2 inhibitors.
Pharmacology
Lumiracoxib selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, which is involved in the production of prostaglandins. Prostaglandins play a key role in the body's inflammatory response. By inhibiting COX-2, lumiracoxib reduces inflammation and pain.
Side Effects
The most common side effects of lumiracoxib include dyspepsia, abdominal pain, nausea, and diarrhea. Serious side effects can include hepatotoxicity, which led to its withdrawal from the market.
History
Lumiracoxib was approved by the European Medicines Agency (EMA) in 2005 but was withdrawn worldwide in 2007 due to concerns about serious side effects, particularly hepatotoxicity.
Related Terms
External links
- Medical encyclopedia article on Lumiracoxib
- Wikipedia's article - Lumiracoxib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski